A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)
No added clinical benefit of berzosertib and topotecan combination was observed over topotecan monotherapy in patients with platinum-resistant SCLC.
Authors
- Federico Cappuzzo (ORCID: https://orcid.org/0000-0002-6295-6767)
- Thomas Grombacher (ORCID: https://orcid.org/0000-0001-9855-7429)
- Y. Cheng (ORCID: https://orcid.org/0009-0007-4791-0051)
- B. Sarholz
- Xiang Da Dong (ORCID: https://orcid.org/0000-0001-9324-1281)
- R. Hallwachs
- Jaume Ferrer (ORCID: https://orcid.org/0000-0002-5635-3628)
- Camilo Moulin
- Ioannis Gounaris (ORCID: https://orcid.org/0000-0003-2755-6597)
- Alejandro Navarro (ORCID: https://orcid.org/0000-0001-5903-270X)
- T. Yoshida
- Jayaprakasam Bolleddula (ORCID: https://orcid.org/0000-0003-4700-7819)
- Luis Paz‐Ares (ORCID: https://orcid.org/0000-0002-1947-3364)
- Yuanbin Chen (ORCID: https://orcid.org/0009-0006-4175-8055)
- N. Yamamoto
- Anish Thomas (ORCID: https://orcid.org/0000-0003-3293-3115)
- N. Reguart
- Sophie Cousin (ORCID: https://orcid.org/0000-0002-4847-6329)
- M. Otte
Institutions
- Union Hospital (HK)
- Merck KGaA, Darmstadt (Germany) (DE)
- Research Institute Hospital 12 de Octubre (ES)
- Merck Serono Ltd. (United Kingdom) (GB)
- Jilin Province Tumor Hospital (CN)
- Merck Serono S.A. (Switzerland) (CH)
- Hospital Clínic de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Institut Bergonié (FR)
- National Cancer Institute (US)
- Hematology Oncology Consultants (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Tokyo National Hospital (JP)
- Huazhong University of Science and Technology (CN)
- Merck Serono S.p.A. (Italy) (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105918
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00